Active ingredient
Risankizumab
6 finished FDA listings contain Risankizumab as their only active ingredient.
FDA NDC Directory
- Ingredient names as written by FDA
- RISANKIZUMAB
- Dosage forms
- Injection, Injection, Solution
- Routes
- Intravenous, Subcutaneous
- Manufacturers / labelers
- 1
- Strengths listed
- 150 mg/ml · 180 mg/1.2ml · 55 mg/.37ml · 600 mg/10ml
- Brand names in FDA listings
- Skyrizi
RxNorm (National Library of Medicine)
Ingredient concept RxCUI 2166040
Drugs@FDA applications
Linked only where the FDA listing’s application number matches Drugs@FDA exactly. A listing in the NDC Directory does not by itself mean FDA approval.
| Application | Sponsor | Original approval | Listings |
|---|---|---|---|
| BLA 761105 | ABBVIE INC | 2019-04-23 | 5 |
| BLA 761262 | ABBVIE INC | 2022-06-16 | 1 |
Official labeling on DailyMed
Sources: FDA NDC Directory (2026-09-29), RxNorm, Drugs@FDA, DailyMed. Each source’s facts are shown separately as published.